Next-Generation Immunopharmacology: Targeting Tumor Microenvironment for Precision Cancer Therapy

Abstract

The tumor microenvironment (TME) has emerged as a central regulator of tumor progression, immune evasion, and therapeutic resistance. Contemporary immunopharmacology has transitioned from tumor-centric approaches to strategies targeting the dynamic interplay between tumor cells and their surrounding microenvironment. This review systematically evaluates recent advances (2020–2025) in TME-targeted therapies, including immune checkpoint inhibitors, adoptive cell therapies, cytokine modulators, and nanomedicine-based delivery systems. A PRISMA-guided systematic analysis and meta-analytical synthesis highlight improved survival outcomes associated with TME modulation. Biomarker-driven precision immunotherapy and combinational strategies are discussed as key drivers of future oncology paradigms. The integration of multi-omics and artificial intelligence is expected to further refine therapeutic targeting. Overall, next-generation immunopharmacology offers a transformative approach toward personalized cancer treatment.